Abstract:Abstract Background: The crucial role of repopulating lymphocytes following allogeneic hematopoietic stem cell transplantation (allo-HSCT), including the prevention of infections and erudiating residual tumor cells in the early post-transplant phase, has been demonstrated. Currently, unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation with T cell repletion has been an established treatment for patients without HLA-matched related or unrelated donors. However, the prognostic significance of early lymphocyte recovery in this transplant settings is not defined. Methods: We retrospectively analyzed the relationship between day 30 absolute lymphocyte count (ALC30) and transplant outcomes in 217 paients with hematological malignancies receiving T-cell-repleted transplantation from an HLA-mismatched/haploidentical related donors. Results: At the time of this analysis, 44 of the cohort patients had died. The choice of ALC ≥ 235 cells/μL as the cut-off value point was supported by the data because it yielded the greatest differential in survival, based on the chi-square (×2=23.448, P<0.0001) analysed at different cut-off points between the 25% and 75% quartiles (190–460 cells/μL) from the log-rank test. The median follow-up was 543 days (range: 150–1873 days). Patients with an ALC ≥ 235 cells/μL (n=136) experienced a superior median OS compared to patients with an ALC < 235 cells/μL (n=81) (median OS, 582 days vs 510 days, respectively, P<0.0001). Two groups were identified based on an ALC of ≥ 235 cells/μL and <235 cells/μL at days 30 post HSCT. There were no statistical differences in patient’s characteristics between the two groups at days 30 taking into accout a P-value of 0.05. One patients (0.46%) failed to neutrophil engraft, 12 patients (5.53%) failed to platelet engraft. The median time to neutrophil and platelet recovery was 13 days (range, 9–49 days) and 16 days (range, 7–356 days), respectively. Eighty-two patients developed grade II to IV acute GVHD with a cumulative incidence of 49%±3.80%. 113 of 160 evaluable patients surviving more than 100 days developed chronic GVHD (limited 82 [51.25%]; extensive 31 [19.38%]) with a cumulative incidence of 63.8%±3.90%. Forty-four of 217 (20.28%) patients died from nonrelapse causes, with a cumulative incidence of TRM of 23.6%±3.40%. In multivariate analysis the ALC30 above the cutoff value 235 cells/μL was associated with improved overall survival (OS) (HR 0.331, 95% CI 0.189–0.578; P<0.0001), leukemia free survival (LFS) (HR 0.299, 95% CI 0.179–0.501; P<0.0001), less relapse (HR 0.345 (95% CI 0.147–0.808); P=0.014), and less transplant-related mortality (HR=0.284; 95%CI 0.148–0.544; P<0.0001). The beneficial effects of a higher ALC30 (≥235 cells/μL) influenced outcomes in patients with both standard and high-risk disease but did not affect relapse in these two groups. The higher ALC30 was also correlated with improved OS and LFS in patients with AML, ALL, and CML, respectively. Conclusion: Our results suggest that the day 30 ALC would appear to be a useful and simple measurement to predict those patients with superior survival after unmanipulated HLA-mismatched/haploidentical transplantation.

Factors which affect the CFU-GM content of the peripheral blood haemopoietic progenitor cell harvests in patients with acute myeloid leukaemia

A Retrospective Study of Autologous Stem Cell Mobilization by G-CSF in Combination with Chemotherapy in Patients with Multiple Myeloma and Lymphoma.

Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone

Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission

Clinical Analysis of the Factors Influencing the Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Acute Leukemia Patients

Chemotherapy Combined With Granulocyte Colony Stimulating Factor (G-Csf) For Mobilization Of Cd34(+) Cells In Lymphoma And Multiple Myeloma Patients

Factors Influencing Engraftment in Hla-Haploidentical/Mismatch Related Transplantation with Combined Granulocyte-Colony Stimulating Factor-Mobilized Peripheral Blood and Bone Marrow for Patients with Leukemia

Biological characterization of CD34+ cells mobilized into peripheral blood

Improved outcomes using <scp>G‐CSF</scp>‐mobilized blood and bone marrow grafts as the source of stem cells compared with <scp>G‐PB</scp> after <scp>HLA</scp>‐identical sibling transplantation in patients with acute leukemia

The More, the Less: Age and Chemotherapy Load Are Predictive of Poor Stem Cell Mobilization in Patients with Hematologic Malignancies

The Inferiority of G-PB to Rhg-Csf-mobilized Blood and Marrow Grafts As a Stem Cell Source in Patients with High-Risk Acute Leukemia Who Underwent Unmanipulated HLA-mismatched/haploidentical Transplantation: a Comparative Analysis

Early Lymphocyte Recovery Predicts Superior Survival After Unmanipulated Hla-Mismatched/Haploidentical Blood And Marrow Transplantation For Patients With Hematological Malignancies

Autologous peripheral blood stem cell harvest timing by absolute neutrophil count in children and young adult patients: Single-institute experience

Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy

Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia.

Early Lymphocyte Recovery Predicts Superior Overall Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation for MDS and Acute Myeloid Leukemia Evolving from MDS

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Effects of CD34+ Cell Dose on Haematopoietic Recovery in Acute Lymphoblastic Leukaemia Patients with Positive Pretransplant Measurable Residual Disease.

Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease

[Factors Affecting Mobilization of Peripheral Blood Stem/progenitor Cells and Apheresis Efficiency from Healthy Donors by Rhg-Csf].

[Peripheral Monocyte Counts at First Collection of Allo-Grafts Predicts Amount of CD34(+) Cells in Mixture of Rhg-Csf Primed Bone Marrow and Mobilized Peripheral Stem Cell Grafts].